Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its Q3 earnings later this week. Analysts are predicting strong performance driven by the continued success of Lilly's blockbuster treatments, particularly the diabetes franchise. However, there are also concerns about potential headwinds from r